Pharmaceutical - Pharmaceutical, Eli Lilly

Filter

Current filters:

PharmaceuticalEli Lilly

Popular Filters

1 to 25 of 198 results

Lilly and Boehringer closing in on diabetes market lead with Jardiance approval

Lilly and Boehringer closing in on diabetes market lead with Jardiance approval

07-08-2014

With the recent approval of Jardiance (empagliflozin) in the USA, Eli Lilly and its partner, German family-owned…

Boehringer IngelheimDiabetesEli LillyEli Lilly and CompanyJanuviaJardianceMarkets & MarketingMerck & CoPharmaceuticalTradjenta

Canadian health authorities approve Abraxane plus gemcitabine for metastatic pancreatic cancer

Canadian health authorities approve Abraxane plus gemcitabine for metastatic pancreatic cancer

06-08-2014

Health Canada has approved US biotech company Celgene’s Abraxane, and gemcitabine, marketed by US drug…

AbraxaneCanadaCancerCelgene Corp.Eli Lillygemcitabine HclMetastatic pancreatic cancerOncologyOrganofluoridesPharmaceuticalRegulation

US FDA approves Jardiance for adults with type 2 diabetes

US FDA approves Jardiance for adults with type 2 diabetes

02-08-2014

The US Food and Drug Administration on Friday approved Jardiance (empagliflozin) tablets as an adjunct…

Boehringer IngelheimDiabetesEli LillyEuropeGermanyJardiancePharmaceuticalRegulationUSA

Eli Lilly to establish production of insulin in Russia

Eli Lilly to establish production of insulin in Russia

29-07-2014

US pharma major Eli Lilly has reached an agreement with one of Russia’s leading drugmakers, R-Pharm,…

DiabetesEli LillyHumulin RInsulinPharmaceuticalProductionR-PharmRussia

Global insulin market set to reach $32.24 billion in 2019

Global insulin market set to reach $32.24 billion in 2019

28-07-2014

The global insulin market was valued at $19.99 billion in 2012 and is expected to expand at a compound…

AfrezzaChinaDiabetesEli LillyGlobalInsulinLY2605541MannKindMarkets & MarketingMerck & CoMK-1293NN1218Novo NordiskPharmaceutical

Eli Lilly 2nd-qtr sales takes hit from generics; net income falls 39%

24-07-2014

US pharma major Eli Lilly reported second quarter 2014 revenues fell 17% to $4.935 billion, reflecting…

Eli LillyFinancialPharmaceutical

UK's NICE changes guidance to recommend Eli Lilly’s Efient for blood clots

UK's NICE changes guidance to recommend Eli Lilly’s Efient for blood clots

23-07-2014

The National Institute for Health and Care Excellence (NICE), the UK’s health care guidance body, has…

Acute coronary syndromesCardio-vascularEfientEli LillyPharmaceuticalprasugrelRegulationUK

Seven pharma companies offer up compounds to UK researchers

Seven pharma companies offer up compounds to UK researchers

22-07-2014

UK researchers will be granted access to a ‘virtual library’ of deprioritized pharmaceutical compounds…

AstraZenecaEli LillyGlaxoSmithKlineJanssenMedical Research CouncilPfizerPharmaceuticalResearchTakeda PharmaceuticalUCBUK

China’s Yabao Pharma partners with Eli Lilly to develop diabetes candidate

China’s Yabao Pharma partners with Eli Lilly to develop diabetes candidate

08-07-2014

Chinese drugmaker Yabao Pharmaceutical has entered a strategic partnership with US pharma major Eli Lilly…

ChinaDiabetesEli LillyLicensingPharmaceuticalYabao Pharmaceutical

Six new drugs recommended for approval by EMA’s CHMP

Six new drugs recommended for approval by EMA’s CHMP

27-06-2014

At its end-June meetings, the European Medicines Agency’s Committee for Medicinal Products for Human…

AbasriaAnti-viralsBristol-Myers SquibbCardio-vascularDaklinzaDiabetesEli LillyEuropeFreseniusGE HealthcarePharmaceuticalRegulationTriumeqVelphoroVifor PharmaVizamyl

Sanofi facing triple threat from Eli Lilly for diabetes treatment market space

Sanofi facing triple threat from Eli Lilly for diabetes treatment market space

26-06-2014

The imminent patent expiration of French pharma major Sanofi’s Lantus (insulin glargine) has opened…

BiosimilarsDiabetesdulaglutideEli LillyIDegLiraLantusLixiLanMarkets & MarketingNovo NordiskPharmaceuticalResearchSanofiToujeo

UK’s NICE draft guidance recommends Lilly’s Efient

UK’s NICE draft guidance recommends Lilly’s Efient

20-06-2014

UK health care watchdog the National Institute for Health and Care Excellence (NICE) has today published…

Cardio-vascularEfientEli LillyPharmaceuticalPricingRegulationUK

Boehringer and Lilly re-file empagliflozin NDA with FDA

Boehringer and Lilly re-file empagliflozin NDA with FDA

19-06-2014

The US subsidiary of German family-owned drugmaker Boehringer Ingelheim and pharma major Eli Lilly have…

Boehringer IngelheimDiabetesEli LillyempagliflozinPharmaceuticalRegulationUSA

ADA 2014: Investigational new insulin glargine from Lilly and Boehringer comparable to Lantus

ADA 2014: Investigational new insulin glargine from Lilly and Boehringer comparable to Lantus

15-06-2014

For the first time, US pharma major Eli Lilly and family-owned German major Boehringer Ingelheim presented…

BiosimilarsBoehringer IngelheimDiabetesEli LillyInsulin Glargine [rDNA origin] InjectionLantusLY2963016PharmaceuticalResearchSanofi

Lilly’s Cyramza disappoints in Ph III liver cancer trial

Lilly’s Cyramza disappoints in Ph III liver cancer trial

12-06-2014

US drug major Eli Lilly (NYSE: LLY) says the Phase III REACH trial of Cyramza (ramucirumab) in patients…

ChemistryCyramzaEli LillyHealth Medical PharmaLillyMajorOncologyOrganic chemistryPharmaceuticalResearch

Sanofi and Lilly announce licensing agreement for Cialis OTC

Sanofi and Lilly announce licensing agreement for Cialis OTC

28-05-2014

French drug major Sanofi and US drug major Eli Lilly have agreed to pursue regulatory approval of non-prescription…

CialisEli LillyEli Lilly and CompanyEuropean Medicines AgencyFranceLicensingMen's HealthPDE5 inhibitorsPharmaceuticalSanofiTreatment of men with erectile dysfunctionVincent Warnery

Boehringer and Lilly’s diabetes drug Jardiance gains EU approval

23-05-2014

German family-owned pharma major Boehringer Ingelheim and US partner Eli Lilly have received Marketing…

Boehringer IngelheimDiabetesEli LillyempagliflozinEuropeJardiancePharmaceuticalRegulation

Lilly's basal insulin peglispro beats insulin glargine in HbA1c reduction for type 2 diabetes

Lilly's basal insulin peglispro beats insulin glargine in HbA1c reduction for type 2 diabetes

13-05-2014

US pharma major Eli Lilly has released positive top-line results of three completed Phase III clinical…

DiabetesEli LillyLantuspeglisproPharmaceuticalResearchSanofi

Lilly to appeal $450 million fine in Brazil labor case

Lilly to appeal $450 million fine in Brazil labor case

10-05-2014

US drug major Eli Lilly revealed on Friday that the 2nd Circuit of the Labor Court of Paulinia in the…

BrazilEli LillyLegalPharmaceuticalProduction

Eli Lilly 1st-qtr 2014 net income plunges, sales down, hit by generic competition

24-04-2014

US pharma major Eli Lilly posted first-quarter 2014 financial results, with revenue declined 16 % to…

Eli LillyFinancialPharmaceutical

UK NICE recommends Giotrif and Velcade, but says “no” to added use of Alimta

23-04-2014

People in England and Wales with lung cancer whose tumors test positive for a mutation will now have…

AlimtaBoehringer IngelheimEli LillyGiotrifJohnson & JohnsonNorthern EuropeOncologyPharmaceuticalPricingRegulationUKVelcade

Lilly's Cyramza first FDA-approved drug for advanced gastric cancer after prior chemo

22-04-2014

The US Food and Drug Administration has approved pharma major Eli Lilly’s Cyramza (ramucirumab) as…

CyramzaEli LillyNorth AmericaOncologyPharmaceuticalRegulationUSA

Novartis swaps products with GlaxoSmithKline, sells unit to Lilly

Novartis swaps products with GlaxoSmithKline, sells unit to Lilly

22-04-2014

In what looks like a significant restructuring of company focuses, Swiss drug major Novartis and UK peer…

Eli LillyGlaxoSmithKlineMergers & AcquisitionsNovartisPharmaceuticalVaccines

1 to 25 of 198 results

Company Spotlight

ImmunoGen

ImmunoGen

Back to top